Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech

Jul 23, 2024•about 2 years ago

Contract Type

partnership

NanjingManufacturingBiotechnologyPharmaceutical

Description

Triastek Inc. has entered into a research collaboration and platform technology license agreement with BioNTech SE to develop RNA therapeutics for oral delivery based on 3D printing technology. The collaboration aims to provide groundbreaking therapies to address unmet medical needs in an easy to administer oral formulation.

Company Information

Company

Triastek

Location

Nanjing, Jiangsu, China

About

Founded in 2015, Triastek, Inc. is the global leader in the 3D printing of pharmaceuticals and is pioneering the implementation of digital pharmaceutical solutions. Triastek’s novel and proprietary 3D printing technology platform, encompasses dosage form design, digital pharmaceutical product development, and intelligent manufacturing. Triastek has the largest product pipeline based on 3D printing technology in the world, with the company’s 1st and 2nd products (T19 and T20) having received IND clearance from the U.S. Food and Drug Administration (FDA). The company also holds the highest number of patent applications related to 3D printing of pharmaceuticals, providing the most comprehensive patent coverage of any 3D printing pharmaceutical company in the world.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Triastek's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.